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Methods: A total of 103 subjects with probable mild AD and 101 healthy controls were recruited at
seven clinical study sites. Subjects were tested using an auditory oddball ERP paradigm.
Results: Subjects with mild AD showed lower amplitude and increased latency for ERP features
associated with attention, working memory, and executive function. These subjects also had
decreased accuracy and longer reaction time in the target detection task associated with the ERP test.
Discussion: Analysis of ERP data showed significant changes in subjects with mild AD that are
consistent with the cognitive deficits found in this population. The use of an integrated hardware/soft-
ware system for data acquisition and automated data analysis methods make administration of ERP
tests practical in outpatient settings.
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Despite the emergence of putative biomarkers for Alz-
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with diagnosis, and assessment of severity and progression.
Event-related potentials (ERP) reflect well-characterized
brain responses to sensory, motor, and cognitive events [3].
As such, ERP methods are well suited to detect and quantify
the cognitive deficits associated with AD [4]. ERP have been
found to be altered in AD beginning in the very early stages
of the disease. ERP tests on young presymptomatic individ-
uals who carry mutations in the presenilin-1, and amyloid
precursor protein genes show significant changes in ERP
patterns years before the onset of behavioral symptoms
and the development of AD [5,6]. ERP have shown
potential utility as biomarkers of disease progression andeimer’s Association. This is an open access article under the CC BY license
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cognitive impairment (MCI). ERP responses to auditory
stimuli contain discriminative information that predicts
which MCI patients are likely to progress to AD [7], and pa-
tients with amnestic MCI that are at high risk of conversion
to AD have abnormal ERP during a word repetition task [8].
ERP have also been shown to reliably track the cognitive
decline associated with AD progression. ERP markers of
cognitive function are increasingly altered in longitudinal
studies on MCI and AD patients [9,10]. Finally, ERP are
sensitive to the effects of cognitive enhancers currently
used for the treatment of AD. ERP measures are reliable
instruments for the assessment of the cognitive response to
cholinesterase inhibitors such as donepezil, while the
effects of the selective N-methyl-D-aspartate (NMDA)
antagonist memantine on ERP correlate with changes in
mini-mental state examination (MMSE) score [11–13].
Although the potential of ERP as a sensitive and reliable
cognitive biomarker for AD has been known for a long time
(for review, see [14–16]), the promise of this technique has
not been yet fully realized through wide adoption of ERP
in clinical use. Primary reasons have been the lack of
standardization of ERP acquisition and data analysis
techniques, and the impracticality of conducting ERP tests
in clinical environments on actual patients. Recent
advances in electronics and analysis algorithms have made
it possible to administer ERP tests in a practical manner.
There is now a need for large population-based studies that
can confirm the usefulness of ERP as cognitive biomarkers
for AD outside the laboratory [6].
In our multicenter clinical study, we investigated whether
ERP collected in an outpatient setting and analyzed with
automated, standardized methods can achieve results equiv-
alent to those reported from academic laboratories and pro-
vide a sensitive and reliable measure of the cognitive deficits
associated with early AD.2. Materials and methods
2.1. Study participants
A total of 103 subjects with probable mild AD and 101
healthy controls (HC) aged between 60 and 90 years were re-
cruited at seven clinical study sites. The study (ClinicalTrials.
gov number NCT00938665) was approved by institutional
review boards for each site, and a written informed consent
was obtained from each study participant.
2.2. Subjects screening
All study subjects received a thorough medical history
and neurologic examination. General inclusion criteria for
the study included a modified Hachinski score4 and a geri-
atric depression scale (GDS) short form score5. Exclusion
criteria were the use of antidepressants other than selective
serotonin uptake inhibitors, major psychiatric disorders,
and clinically significant neurologic diseases other thanAD. Subjects taking sedatives and/or memory dietary sup-
plements were asked to suspend them for the 72 hours before
screening and testing.
The diagnosis of probable AD was made on the basis of
the National Institute of Neurological and Communication
Disorders and the Stroke-Alzheimer’s Disease and Related
Disorders Association criteria [17]. The inclusion criteria
for the AD cohort were designed to recruit subjects in the
early stages of the disease and encompassed anMMSE score
between 21 and 26, a clinical dementia rating (CDR) score of
0.5, 1, or 2, and an education adjusted score on the delayed
recall of the Wechsler logical memory II subscale of 3 for
0–7 years of education, 5 for 8–15 years of education, and
9 for 16 or more years of education.
Inclusion criteria for the HC cohort were an MMSE score
of 27 and above, a CDR score of 0, and an education
adjusted score on the delayed recall of the Wechsler logical
memory II subscale of4 for 0–7 years of education,6 for
8–15 years of education, and 10 for 16 or more years of
education.2.3. Experimental paradigm
Subjects who met inclusion criteria at screening were
tested using a three-stimulus oddball paradigm (for review,
see [18,19]).
Stimuli comprised of standard tones (1000 Hz), target
tones (2000 Hz), and unexpected distractor tones (white
noise) that were played with probabilities of .75, .15, and
.10. Tones were presented in pseudorandom order, so that
target and distractor tones were never presented sequentially
[20]. Subjects were instructed to respond to the target stimuli
by pressing a button with their dominant hand. For each test,
between 300 and 400 stimuli were presented binaurally
through insert ear phones at 70-dB volume. The tone duration
for each stimulus was 100 ms with rise and fall times of
10 ms. The interstimulus interval was randomized between
1.5 and 2 s. During the test, subjects sat comfortably in a chair
in an office room under regular lighting conditions. One HC
and four mild AD subjects whowere unable to follow instruc-
tions were excluded from all statistical analyses.2.4. Testing procedures and data analysis
Electroencephalographic (EEG) activity was recorded
from 7 electrode sites (Fz, Cz, Pz, F3, P3, F4, and P4) of
the international 10-20 system [21] using a COGNISION
Headset (Neuronetrix). Electrodes were referenced to aver-
aged mastoids (M1, M2), and Fpz served as the common
electrode. The headset used for data collection has been vali-
dated to perform reliable ERP recordings when skin contact
impedance is,70 kU, a practical requirement for recording
in standard office environments. Impedance was automati-
cally checked at all electrodes after each target or distractor
tone, and was kept below this limit throughout each test.
Data were collected from 2240 to 1000 ms around the
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35 Hz. An automatic artifact threshold detection limit of
6100 mV was set for the tests. Trial sets of a deviant tone
and the immediately preceding standard tones (epoch sets)Fig. 1. Grand average ERPs for standard, target, and distractor stimuli in mild AD
site where they were found to be more prominent. Abbreviations: ERP, event-relawith artifacts exceeding the threshold were rejected in real
time and immediately repeated.
Trial averaging and extraction of ERP measures were auto-
matically performed by the COGNISION System softwareand HC subjects. ERP features for each stimulus are shown at the electrode
ted potentials; HC, healthy controls; AD, Alzheimer’s disease.
Table 1
Demographic and clinical characteristics of study participants
Characteristics HC (n 5 100) AD (n 5 99)
Age 73.2 6 0.71 76.2 6 0.74*
Male (%) 40 48.5
Education (y) 14.9 6 0.29 14.4 6 0.32
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using the prestimulus period [6,22] and averaged according
to stimulus. For standard tones, only the trials immediately
preceding target and distractor stimuli were averaged.
During data preprocessing, recordings that exceeded two
times the root mean square value (RMS) for the EEG test
data or with wrong button presses were rejected and excluded
from averaging. ERP waves that averaged less than 20 trials
after preprocessing were eliminated from all analyses [23].
Peak amplitude of the ERP features was measured as the
difference between the mean prestimulus baseline and
maximum peak amplitude. Peak latency was defined as the
time point corresponding to the maximum amplitude and
was calculated relative to stimulus onset [24,25]. P50 and
N100 were measured from all stimuli. P200 was measured
from standard and target tones. N200, P3b, and slow wave
were measured from the target tone and P3a from the
distractor tone (Fig. 1).
TheP50ERPfeaturewasdefinedas themaximumpositivity
between 24 and 72 ms poststimulus, N100 was the maximum
negativity between 70 and 130ms, P200 themaximumpositiv-
itybetween180and235ms, andN200 themaximumnegativity
between 205and315ms.TheP3awas defined as themaximum
positivity between 325 and 500 ms, and the P3b as the
maximum positivity between 325 and 580 ms. Finally, the
slow wave was the maximum negativity between 460 and
680ms.All timewindowswere determined by inspecting indi-
vidual averages and group grand averages [26].
The feature extraction algorithm used for the analysis
defined a maximum positivity as the highest point in the
measurement window that was surrounded on both sides
by lower voltage. If a maximum positivity was not present
in the time window chosen for an ERP feature, the algorithm
would not select a peak for that channel.
Together with peaks amplitude and latency, the algorithm
for data analysis also calculated mean amplitude for the ERP
features of interest, defined as the average voltage over the
specified measurement window for each ERP feature [27].
Finally, accuracy and reaction time of button presses were
also analyzed. Accuracy was calculated as the percent of
correct responses to target tones, whereas false alarms indi-
cated button presses to nontargets. Reaction time was calcu-
lated as the time from stimulus onset to button press. Median
reaction times were calculated for each subject to limit the
influence of any outlier reaction times [5].MMSE 29.1 6 0.08 23.4 6 0.19**
CDR 0.0 6 0.0 0.9 6 0.03**
WMS-R logical memory
Immediate recall 14.6 6 0.31 5.3 6 0.33**
Delayed recall 13.7 6 0.33 2.1 6 0.24**
GDS 0.8 6 0.11 2.3 6 0.16**
Hachinski 0.6 6 0.07 0.6 6 0.07
Abbreviations: HC, healthy controls; AD, mild Alzheimer’s disease;
MMSE, mini-mental state examination; CDR, clinical dementia rating;
WMS-R, Wechsler memory scale-revised; GDS, geriatric depression
scale; SEM, standard error of the mean.
NOTE. Data are represented as mean 6 SEM. *P , .05 and **P , .01
compared with HC after Bonferroni correction.2.5. Statistical analysis
Group comparisons were analyzed using c2 test and Stu-
dent t test for categorical and quantitative variables, respec-
tively. Age was significantly different between mild AD and
HC groups and was used as a covariate in all statistical com-
parisons where data correlated with age. P values,.05 were
considered significant. When multiple comparisons were
performed, a Bonferroni correction was applied to control
for type I error and the adjusted P values were reported.Correlations between ERP component values were analyzed
using Pearson correlation coefficients.3. Results
3.1. Demographics and clinical data
There were no significant differences in gender and edu-
cation between study groups. Age, however, was higher on
average in subjects with mild AD (t 5 2.94, P , .05).
Statistical comparison of clinical data between groups
showed, as expected, lower MMSE (t 5 228.93, P , .01),
lower Wechsler logical memory (t 5 220.28, P , .01 and
t 5 228.38, P , .01 for immediate and delayed recall,
respectively), and higher CDR (t 5 30.54, P , .01) scores
in subjects with mild AD. These subjects also had a higher
GDS (t 5 7.32, P , .01), whereas the Hachinski score was
similar between groups (Table 1).
3.2. ERP test
Morphology of the grand average waves for standard,
target, and distractor stimuli was different between groups
(Fig. 1). The differences were larger for target and distractor
tones, and for the late cognitive responses than for the early
sensory measures (Supplementary Fig. 1).
Statistical comparisons for ERP features in mild AD
versus HC are listed in Table 2. Age correlated with N100,
P3b, and P3a latency measures (R2 .0.05), and was used
as covariate in comparisons for these ERP measures.
Analysis of ERP features for the standard tone showed
lower N100 amplitude (t 5 6.25, P , .01) and P200 ampli-
tude (t523.39, P, .01) in the mild AD group. This group
of subjects also had higher P50 (t5 3.68, P, .01) and lower
N100 average amplitudes (t 5 5.50, P , .01) than HC.
Comparisons for the target tone indicated that subjects with
mild AD had lower N100 amplitude (t5 4.88, P, .01), lower
P3b amplitude (t 5 25.65, P , .01), and a more negative
N200 peak (t 5 23.38, P , .01) than HC. This group of
Table 2
ERP features in HC and mild AD
ERP feature Stimulus
Amplitude (mV) Latency (ms) Average amplitude (mV)
HC AD HC AD HC AD
P50 Standard 2.77 6 0.08 2.95 6 0.08 44.8 6 0.4 44.3 6 0.4 0.29 6 0.06 0.60 6 0.06**
N100 Standard 27.23 6 0.14 26.00 6 0.14** 93.0 6 0.4 95.2 6 0.5 24.56 6 0.11 23.73 6 0.11**
P200 Standard 5.26 6 0.14 4.64 6 0.12** 214.5 6 1.0 211.7 6 0.8 3.44 6 0.11 3.14 6 0.10
P50 Target 2.79 6 0.09 2.79 6 0.09 42.6 6 0.5 43.2 6 0.5 0.36 6 0.06 0.52 6 0.07
N100 Target 26.64 6 0.14 25.63 6 0.15** 95.2 6 0.5 98.6 6 0.6 24.25 6 0.12 23.43 6 0.12**
P200 Target 4.49 6 0.18 4.86 6 0.18 202.8 6 0.9 201.2 6 0.9 2.35 6 0.13 2.61 6 0.14
N200 Target 20.31 6 0.17 21.10 6 0.16** 251.1 6 1.3 257.9 6 1.5** 2.84 6 0.14 1.93 6 0.13**
P3b Target 6.03 6 0.20 4.42 6 0.20** 396.0 6 2.8 419.6 6 3.3* 1.92 6 0.16 1.40 6 0.13w
Slow wave Target 22.54 6 0.20 22.65 6 0.18 563.6 6 2.5 575.4 6 3.2* 20.02 6 0.15 0.19 6 0.15
P50 Distractor 3.70 6 0.09 3.35 6 0.10* 45.2 6 0.6 47.6 6 0.6* 1.18 6 0.08 1.26 6 0.09
N100 Distractor 25.34 6 0.14 24.47 6 0.15** 101.1 6 0.5 103.9 6 0.5 22.84 6 0.11 22.21 6 0.12**
P3a Distractor 5.88 6 0.19 3.63 6 0.20** 417.3 6 2.4 419.8 6 3.0 3.40 6 0.15 1.26 6 0.13**
Abbreviations: ERP, event-related potentials; HC, healthy controls; AD, mild Alzheimer’s disease; SEM, standard error of the mean.
NOTE. Data are represented as mean 6 SEM.wP , .1; *P , .05; and **P , .01 compared to HC after Bonferroni correction.
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with longer latencies for the N200 (t 5 3.43, P , .01), P3b
(t5 2.66,P, .05), and slowwave (t5 2.88,P, .05). Finally,
data for average amplitude showed lower N100 (t 5 4.99,
P , .01), lower N200 (t 5 24.73, P , .01), and a tendency
to lower P3b (t 5 22.47, P , .1) in subjects with mild AD,
thus closely resembling amplitude data.
When ERP features for the distractor tone were analyzed,
statistical comparisons showed decreased amplitude (t522.55,
P , .05) and longer latency (t 5 2.83, P , .05) for the P50
in subjects with mild AD. These subjects also had smaller
N100 and P3a amplitudes (t 5 4.24, P , .01 and
t 5 28.07, P , .01) and average amplitudes (t 5 3.57,
P , .01 and t 5 210.68, P , .01, respectively).
A follow-up single-channel analysis at midline electrodes
for the ERP features that were statistically different between
groups showed that changes in N100 measures were pro-
nounced at the frontal and central electrode sites, whereas
changes in P3a and P3b ERP features were more prominent
at the central and parietal electrodes (Table 3).
When performance in the target detection task associated
with the ERP test was analyzed, there were significant differ-
ences between groups. Subjects with mild AD had a lower
percentage of correct responses to target tones (t 5 24.61,
P , .01), a higher number of button presses to nontargets
(t 5 3.43, P , .01), and a longer reaction time for accurate
button presses than HC (t 5 2.4, P , .05; Table 4).
Finally, analysis of correlations across ERP features that
were significantly different between groups showed overall
low Pearson coefficients. Exceptions were N100 measures
across different stimuli, and correlations among amplitude
and average amplitude for the same ERP measure
(Supplementary Table 1).4. Discussion
Study results showed significant differences in ERP
measures between subjects with mild AD and HC. The groupdifferences included both ERP features extracted from the
average waves for the test stimuli and behavioral measures
from the target detection task.
The most widely investigated and best understood
changes in ERP in mild AD are related to the P3b, or classic
P300. This ERP feature is elicited when a deviant stimulus is
associated with a task and reflects an update in working
memory (for review of the neuropsychological origins of
the P3b, please see [28]). The P3b amplitude is determined
by the amount of attentional resources allocated when work-
ing memory is updated [29]. The P3b latency reflects stim-
ulus evaluation and classification speed [30,31]. The
majority of studies that have looked at differences in P3b
between AD subjects and HC have found that P3b
amplitude was typically smaller, and P3b latency was
longer in subjects with AD (for an overview, please see
[32]). Consistent with our results, when subjects were
administered an auditory oddball paradigm where discrimi-
nation of standard and target tones was easy, group differ-
ences were larger for P3b amplitude than latency [32].
Together with the P3b, other significant changes in the
ERP wave for the target tone included longer latencies for
the N200 and slow wave, and a more negative N200 in sub-
jects with mild AD.
The N200 is a negative peak that immediately precedes
the P3b. This ERP feature is linked to the cognitive processes
of stimulus identification and distinction [33] and its peak la-
tency has been shown to correlatewith measures of executive
function and attention [34]. Published studies have reported
delayed latency [34] and smaller amplitude [9] for the N200
in AD. Indeed, N200 latency has proven useful in separating
AD subjects from subjects with MCI and HC [34], and N200
amplitude has been used in combination with P300 latency to
track longitudinal changes in overall cognitive function in
MCI [9]. Our findings offer further evidence that both the
peak latency and amplitude are affected in AD.
The slow wave is a negative deflection that follows the
P3b. This ERP feature has frontal and central scalp
Table 3
Statistically significant differences between groups at single midline
electrodes
ERP
feature Stimulus Type Loc. HC AD P value
P3a Distractor Av. Ampl. Cz 4.03 6 0.42 1.32 6 0.35 ,.001
P3a Distractor Av. Ampl. Pz 4.31 6 0.34 2.22 6 0.32 ,.001
P3a Distractor Amplitude Cz 6.96 6 0.50 3.98 6 0.49 ,.001
P3a Distractor Amplitude Pz 7.01 6 0.42 4.54 6 0.46 ,.001
N100 Standard Amplitude Fz 29.69 6 0.31 28.01 6 0.35 .001
N100 Standard Amplitude Cz 28.78 6 0.33 27.20 6 0.32 .002
P3a Distractor Av. Ampl. Fz 2.76 6 0.42 0.77 6 0.41 .003
N100 Standard Av. Ampl. Fz 26.47 6 0.24 25.35 6 0.28 .007
P3b Target Amplitude Pz 7.36 6 0.39 5.74 6 0.38 .010
N100 Standard Av. Ampl. Cz 25.64 6 0.24 24.60 6 0.26 .012
N100 Target Av. Ampl. Cz 25.26 6 0.28 24.12 6 0.29 .015
N100 Standard Amplitude Pz 24.82 6 0.26 23.87 6 0.24 .025
N100 Target Amplitude Cz 28.03 6 0.37 26.74 6 0.36 .028
N100 Target Amplitude Pz 24.32 6 0.25 23.39 6 0.26 .034
N100 Distractor Amplitude Fz 26.85 6 0.39 25.39 6 0.44 .039
P3b Target Latency Pz 395.8 6 6.2 419.3 6 7.6 .049
Abbreviations: Loc., electrode location according to the 10/20 system;
HC, healthy controls; AD, mild Alzheimer’s disease; Av. Ampl, average
amplitude; SEM, standard error of the mean.
NOTE. Data are represented as mean 6 SEM. P values shown are
adjusted using the Bonferroni correction for multiple comparisons. Only
significant differences between groups are shown.
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tion [35]. The slow wave amplitude correlates with task de-
mands and it is inversely correlated to stimulus detection
accuracy, suggesting that an increase in peak amplitude
might reflect the need for further stimulus processing. The
slow wave latency is affected by task difficulty, and the rela-
tive ease of categorizing events in an oddball test probably
accounts for the early onset and short duration of the slow
wave in this ERP paradigm [35]. In our study, slow wave la-
tency was delayed in mild AD. Our data are consistent with a
previous report of increased slow wave latency in MCI [9]
and suggest that AD subjects might require more time for
stimulus processing than HC.
Contrary to the P3b, reports on the effects of AD and other
dementias on P3a amplitude and latency are scarce, and the
findings have been to some extent inconsistent [26,36,37].
The P3a is associated with engagement of attention and
processing of novelty [28]. The peak amplitude is a measure
of focal attention and has been shown to positively correlate
with executive function [38]. The P3a latency reflects orien-
tation to a nontarget deviant stimulus [16]. Our data show aTable 4
HC and mild AD performance in the behavioral task of the ERP test
Behavioral measure HC AD
Button press accuracy (%) 94.1 6 1.1 82.2 6 2.3**
False alarms (%) 1.1 6 0.2 4.9 6 1.1**
Median reaction time (ms) 458.6 6 11.4 499.5 6 12.6*
Abbreviations: HC, healthy controls; AD,mild Alzheimer’s disease; ERP,
event-related potentials; SEM, standard error of the mean.
NOTE. Data are represented as mean 6 SEM. *P , .05 and **P , .01
compared with HC after Bonferroni correction.reduction of P3a amplitude in subjects with mild AD that is
consistent with reports of decreased attention and executive
function in neuropsychological testing in this population
[39]. Moreover, the large group differences in P3a amplitude
together with reports of a decline in attention and some exec-
utive skills very early in the disease [40,41] suggest that this
ERP feature could be a useful measure of cognitive deficit
from the preclinical stage of AD.
Like for the P3a, N100 amplitude also showed a large
decrease in the mild AD group. The effect was present in
response to all stimuli. Although the N100 reflects bottom-
up information such as stimulus characteristics [42,43], it is
modulated by attention and memory-related variables
[44,45]. Thus, it is possible that the lower amplitude of the
N100 in subjects with mild AD might reflect attention and
memory deficits in these subjects. Indeed, neuropathologic
studies show that sensory cortices are typically spared until
the advanced stages ofAD [46].Adecrease inN100 amplitude
could reflect changes in regulatory inputs from brain regions
that are involved in higher cognitive processes and are more
directly affected by the disease in its early stages. For example,
the prefrontal cortex and the nucleus basalis have been shown
to modulate auditory cortical responses to sound [47,48].
In addition to changes in the ERP wave, subjects with mild
AD also showed decreased performance in the behavioral task
associated with the ERP test. This group of subjects had lower
button press accuracy and longer reaction time. Previous work
by Polich and Corey-Bloom [32] has shown increased
response time and error rate in AD patients across different
auditory and visual oddball paradigms.Our data confirm these
findings in patients tested in outpatient settings and suggest
that results from the behavioral task of the ERP test could
help discriminate subjects with mild AD from healthy aging.
Scientific literature on the neuropsychology of ERP mea-
sures indicates that the different ERP features collected with
an oddball paradigm provide complimentary information
[49]. Indeed, in our study, correlations between ERP features
that showed significant group differences were overall quite
low, suggesting that data from a single test can be used to
assess deficits in several cognitive domains affected by AD.
Automated data analysis methods such as the ones used in
the present study make extraction of multiple ERP features
from data sets practical, thus providing a fast and reliable
method to look at multiple sensory and cognitive measures.
Although correlations across different ERP features were
generally low, correlations between each feature amplitude
and average amplitude were high. These data suggest that
an ERP feature average amplitude likely shares the same
functional interpretation with its amplitude, and can be
used as a proxy measure to confirm amplitude data, or in sit-
uations where an ERP peak might be difficult to identify.5. Conclusion
Analysis of data collected from this large multicenter
study closely reflects findings reported from research
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AD. In addition, the study also offers insights on additional
ERP differences in HC versus mild AD that to our knowledge
had not yet been reported, or for which there did not seem to
be a consensus. Follow-ups will include a classification-based
analysis to measure sensitivity and specificity of ERP in diag-
nosing subjects with early AD in outpatient settings and a
separate study to correlate ERP measures with neuropsycho-
logical tests that are widely used to assess cognitive status.
Data for the study were collected in outpatient settings
from nonspecialized personnel. Our results suggest that the
use of an integrated hardware/software system for ERP
testing and automated data analysis tools can address the
practical limitations that have hindered a wide adoption of
electrophysiological measures as useful biomarkers for AD
outside research laboratories.Acknowledgments
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1. Systematic review: Since the 1970s, a large scientific
literature has shown that event-related potentials
(ERP) can provide a sensitive, physiological measure
of the cognitive deficits associated with Alzheimer’s
disease (AD). However, the use of ERP in AD has
been mostly limited to studies conducted at a single
site and/or on a limited number of subjects. There is a
need for large population-based studies that can
confirm the usefulness of ERP as biomarkers for AD
in outpatient settings.
2. Interpretation: Findings from our multicenter clinical
study show that ERP collected with standard
methods and analyzed using automated data analysis
tools provide a sensitive and practical measure of the
cognitive deficits associated with early AD.
3. Future directions: Additional analysis of the ERP
data from the study, using classification-based ma-
chine learning approaches, will provide further
insight on the sensitivity and specificity of ERP in
diagnosing subjects with early AD in outpatient
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